Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.8
Commitments and Contingencies (Details Textual) (USD $)
3 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 6 Months Ended 0 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 0 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Jan. 20, 2014
Dec. 31, 2013
Jan. 27, 2014
Manufacturing Agreement [Member]
Jun. 30, 2014
Manufacturing Agreement [Member]
Jun. 30, 2014
Rental Agreement [Member]
Jun. 30, 2014
Abbott Biotherapeutics Corp [Member]
Product Development and Patent License Agreement [Member]
Jun. 30, 2014
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Jun. 30, 2014
Abbott Biotherapeutics Corp [Member]
After First Net Sales [Member]
Product Development and Patent License Agreement [Member]
Jun. 30, 2014
Abbott Biotherapeutics Corp [Member]
Phase I Clinical Trial of a licensed product [Member]
Dec. 31, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
Mar. 27, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
Jun. 30, 2014
Oak Ridge National Laboratory [Member]
Jun. 30, 2014
Oak Ridge National Laboratory [Member]
2013 [Member]
Jun. 30, 2014
Oak Ridge National Laboratory [Member]
2014 [Member]
May 16, 2013
Aptiv Solutions [Member]
Oct. 22, 2012
Aptiv Solutions [Member]
Aug. 06, 2012
Aptiv Solutions [Member]
Dec. 31, 2007
Aptiv Solutions [Member]
Jun. 30, 2014
Aptiv Solutions [Member]
Dec. 31, 2012
Aptiv Solutions [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Jun. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Jun. 30, 2013
Fred Hutchinson Cancer Research Center [Member]
license and sponsored research agreement [Member]
Jun. 30, 2014
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Dec. 31, 2013
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Jul. 19, 2012
Fred Hutchinson Cancer Research Center [Member]
Clinical Trial Agreement [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Maximum [Member]
license and sponsored research agreement [Member]
Jun. 15, 2012
Fred Hutchinson Cancer Research Center [Member]
Minimum [Member]
license and sponsored research agreement [Member]
Aug. 28, 2012
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
patients
Jul. 31, 2013
University of Texas M.D. Anderson Cancer Center [Member]
Clinical Trial Agreement [Member]
Sep. 26, 2012
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
Jun. 30, 2014
Johns Hopkins University [Member]
Clinical Trial Agreement [Member]
Nov. 21, 2012
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
Dec. 31, 2013
University of Pennsylvania [Member]
Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)                                                                            
Net sales in milestones payment                       $ 10,000,000                         $ 1,000,000                          
License fee payment                   3,000,000                                                        
Milestones payments                   7,750,000 1,500,000   750,000                                                  
Description of royalty payment                   Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.                               Royalty payments of 2% of net sales will be due to FHCRC.                        
Royalty of Net Sales Percentage                   12.00%                             2.00%                          
First commercial sale period                   12 years 6 months                                                        
Purchase of radioactive material used for research and development                               233,100 300,000 400,000                                        
Project estimated cost for clinical trials of drug Ac-225-HuM195             2,813,960 2,100,000                     2,200,000 2,200,000 2,200,000   1,100,000                              
Down payment of project estimated cost percentage                                             12.50%                              
Down payment for project                                         1,900,000 239,000   239,000                            
Clinical trial cost for approval of food and drug administration                                                             23,500,000 13,200,000            
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )                                                 150,000                          
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )                                                 250,000                          
Number of Patients                                                                 24          
Amount paid to each patient after Completing clinical trial                             31,185                         16,000   31,366     500,000 34,383 38,501    31,771  
Start-up fee for clinical trial                           79,623                             19,749       33,946   22,847   16,000  
Start-up due cost paid date                                                                 Dec. 31, 2013          
Non - refundable institutional fee             562,790                                                   14,500          
Annual pharmacy fee                                                                     2,025      
Amendment processing fee                                                                     500      
Notice period for termination of agreement                 This agreement terminates on July 6, 2014. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.                                                          
Rental agreement renewal description                 The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.                                                          
Accrued expenses                                                                           16,000
Accrued fees paid                                                                         16,000  
Research recorded fees 2,001,937 509,262 4,462,905 1,594,968                                           75,000 75,000                      
Total project estimated to cost         800,000                                                                  
Research and development costs 100,000                                                                          
Security deposit $ 34,733   $ 34,733     $ 0